

Dr. Grosset Replies for the Isoprodiol Study Group

TO THE EDITOR:

The questions raised by Dr. Verduin are highly pertinent. However they are difficult to answer. First, the majority of the patients included in the Isoprodiol study were not newly diagnosed patients. Second, the study was not a field trial but, to the contrary, a double-blind controlled clinical trial aiming to demonstrate whether or not the addition of isoniazid was detrimental. Only patients selected for possible supervised daily intake of drugs were included. Therefore, in their

conclusion, the authors have been careful enough neither to extrapolate their findings to routine field conditions nor to recommend that thioamide-containing regimens should replace the World Health Organization-recommended regimens.

—Jacques H. Grosset, M.D.

*Departement de Bacteriologie-Virologie
Faculte de Medecine Pitie-Salpetriere
91 Blvd. de l'Hopital
75634 Paris 13, France*